Evidence map›Paper›PMID 37344596›Full record

ArticleNature2023

Y chromosome loss in cancer drives growth by evasion of adaptive immunity.

Hany A Abdel-Hafiz, Johanna M Schafer, Xingyu Chen, Tong Xiao, Timothy D Gauntner, Zihai Li, Dan Theodorescu

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 144 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
144citing papers in PubMed, 2 pooled it
28.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

144 citing papers in PubMed, 2 syntheses or guidelines pooled it, 161 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Mosaic loss of Y chromosome associates with lung function, emphysema, and epigenetic aging.American journal of respiratory and critical care medicine · 2026
    Article
  18. Article
  19. Article
  20. Review

84 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Hany A Abdel-Hafiz *Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-5402-5540
Johanna M Schafer *Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-The James, Columbus, OH, USA.ORCID 0000-0001-7834-5621
Xingyu Chen *Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Tong XiaoPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-The James, Columbus, OH, USA.
Timothy D GauntnerPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-The James, Columbus, OH, USA.ORCID 0000-0002-4745-2130
Zihai LiPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-The James, Columbus, OH, USA.ORCID 0000-0003-4603-927X
Dan TheodorescuDepartment of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. dan.theodorescu@cshs.org.ORCID 0000-0002-8708-8206
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USCedars-Sinai Medical Center · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
The Role of the Y Chromosome in Bladder Tumor Development, Growth And ProgressionP01CA278732 · NCI · CEDARS-SINAI MEDICAL CENTER · PI Hany Abdel-Malek Abdel-Hafiz · 2023 to 2026
$10.7M
Understanding the RhoGDI2 metastasis suppressor geneR01CA143971 · NCI · UNIVERSITY OF COLORADO DENVER · PI THEODORESCU, DAN · 2010 to 2020
$4.4M
Molecular chaperones and immune toleranceR01AI077283 · NIAID · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI LI, ZIHAI · 2009 to 2021
$3.7M
Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial MetabolismR01CA262388 · NCI · OHIO STATE UNIVERSITY · PI DENKO, NICHOLAS C., LI, ZIHAI · 2021 to 2025
$3.6M
Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy SupplementR01CA262069 · NCI · OHIO STATE UNIVERSITY · PI LI, ZIHAI · 2021 to 2025
$2.9M
NCI NIH HHS P01 CA278732NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA143971NCI NIH HHS R01 CA262069NCI NIH HHS R01 CA262388NIAID NIH HHS R01 AI077283
6 · The paper itself

Abstract

Loss of the Y chromosome (LOY) is observed in multiple cancer types, including 10-40% of bladder cancers

Indexed as

CD8-Positive T-LymphocytesChromosome DeletionChromosomes, Human, YTumor EscapeUrinary Bladder NeoplasmsAnimalsCRISPR-Cas SystemsFlow CytometryGene EditingGene Expression ProfilingGenomicsHumansImmune Checkpoint InhibitorsImmunotherapyIn Vitro TechniquesMiceImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Identifiers

PMID37344596
PMCPMC10975863
OpenAlexW4381489278

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.